Portfolio company
Cispoly
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops methylation detection kits for the early diagnosis of gynaecological cancers for healthcare providers and public health initiatives.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Digistain
This company develops a diagnostic test using infrared spectroscopy to provide breast cancer recurrence-risk stratification for oncologists and multidisciplinary clinical teams.
ORISDX
This company develops non-invasive salivary diagnostic tests for early oral cancer detection, serving dentists, oncologists and primary care providers.
Zilico
This company develops electrical impedance spectroscopy systems for healthcare providers to deliver real-time cervical cancer diagnostics.
Epiliquid
This company develops blood-based liquid biopsy tests for early cancer detection and monitoring, serving clinical laboratories and medical practitioners.
Glycanostics
This digital health company develops non-invasive liquid biopsy tests for early-stage cancer detection, serving clinical laboratories, hospitals and oncology professionals.
Sakura MedTech
This company develops a tampon-shaped imaging device for cervical cancer screening to replace the traditional speculum for clinicians and their patients.
Syndex Bio
This company develops a polymerase chain reaction platform that amplifies DNA methylation patterns for clinicians and researchers involved in early disease detection.
Oncoliq
This company develops liquid biopsy tests using molecular biology and machine learning for early cancer detection in clinical and screening settings.
